Menu
Back to Journals » Drug Design, Development and Therapy » Volume 15
The Risks of miRNA Therapeutics: In a Drug Target Perspective [Erratum]
Zhang S, Cheng Z, Wang Y, Han T. Drug Des Devel Ther. 2021;15:721–733.
The authors have advised that there are errors on page 722:
Comparison of miRNA Drugs and siRNA Drugs section, first paragraph, “However, 57 siRNA drugs (targeting human proteins/genes) were ongoing or completed clinical trials, including 16 phase I, 16 phase II, eight phase III, 23 terminated/suspended therapeutics (Table 2 and Figure 1A)” should read “However, 65 siRNA drugs are in or have completed clinical trials, including 16 therapeutics in Phase I, 16 in Phase II, 8 in Phase III, 2 approvals, and 23 terminated/suspended (Table 2 and Figure 1A)”.
Comparison of miRNA Drugs and siRNA Drugs section, second paragraph, “Beyond our expectation, the targets of the miRNA drug ranged from 30 to 250 in number and almost all miRNA drug* were over 500 and ven 1000, but the si0052NA drug generally targets 1–3 genes (Figure 2B)” should read “Beyond our expectation, the targets of the miRNA drug ranged from 30 to 250 in number and almost all miRNA drug* had over 500 and even 1000 targets, whereas the siRNA drug generally targeted only 1–3 genes (Figure 2B)”.
These errors were introduced by the Editorial staff during the publication process.
© 2021 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.